CA2382499A1 - Method for coupling molecules - Google Patents

Method for coupling molecules Download PDF

Info

Publication number
CA2382499A1
CA2382499A1 CA002382499A CA2382499A CA2382499A1 CA 2382499 A1 CA2382499 A1 CA 2382499A1 CA 002382499 A CA002382499 A CA 002382499A CA 2382499 A CA2382499 A CA 2382499A CA 2382499 A1 CA2382499 A1 CA 2382499A1
Authority
CA
Canada
Prior art keywords
chemical compound
group
compound according
formula
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002382499A
Other languages
English (en)
French (fr)
Inventor
Michael John Gait
Dmitry Stetsenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9920397.8A external-priority patent/GB9920397D0/en
Priority claimed from GB0012083A external-priority patent/GB0012083D0/en
Application filed by Individual filed Critical Individual
Publication of CA2382499A1 publication Critical patent/CA2382499A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002382499A 1999-08-27 2000-08-25 Method for coupling molecules Abandoned CA2382499A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9920397.8 1999-08-27
GBGB9920397.8A GB9920397D0 (en) 1999-08-27 1999-08-27 Method for coupling molecules
GB0012083A GB0012083D0 (en) 2000-05-18 2000-05-18 Method for coupling molecules
GB0012083.2 2000-05-18
PCT/GB2000/003306 WO2001015737A2 (en) 1999-08-27 2000-08-25 Method for coupling molecules

Publications (1)

Publication Number Publication Date
CA2382499A1 true CA2382499A1 (en) 2001-03-08

Family

ID=26244310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382499A Abandoned CA2382499A1 (en) 1999-08-27 2000-08-25 Method for coupling molecules

Country Status (5)

Country Link
EP (1) EP1207909A2 (ja)
JP (1) JP2003508450A (ja)
AU (1) AU6853900A (ja)
CA (1) CA2382499A1 (ja)
WO (1) WO2001015737A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7569392B2 (en) 2004-01-08 2009-08-04 Vanderbilt University Multiplex spatial profiling of gene expression
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
JP7194635B2 (ja) * 2019-04-25 2022-12-22 あおみ建設株式会社 隙間の充填工法

Also Published As

Publication number Publication date
JP2003508450A (ja) 2003-03-04
WO2001015737A3 (en) 2001-11-15
EP1207909A2 (en) 2002-05-29
AU6853900A (en) 2001-03-26
WO2001015737A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
US10793605B2 (en) Conformationally-preorganized, miniPEG-containing γ-peptide nucleic acids
CA2247889C (en) Method for the synthesis of poly-pyrrole and poly-imidazole carboxamides on a solid support
AU747998B2 (en) Complex formation between dsDNA and oligomer of heterocycles
WO2019035971A1 (en) 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE DERIVATIVES AS TOLL 7 RECEPTOR IMMUNOSTIMULATING AGONISTS (TLR7)
WO2019209811A1 (en) Macrocyclic toll-like receptor 7 (tlr7) agonists
JPH06506945A (ja) ペプチド核酸
JPWO2006088248A1 (ja) ポリオキシアルキレン誘導体
JP2016534099A (ja) アミノ酸誘導体
AU2010248206A1 (en) Lysine compounds and their use in site- and chemoselective modification of peptides and proteins
US20230148277A1 (en) Disulfide bond containing compounds and uses thereof
Brown et al. Conjugation of an oligonucleotide to Tat, a cell-penetrating peptide, via click chemistry
CN110974975B (zh) 一种快速释放的抗体药物偶联物
US20120035362A1 (en) Phosphoramidite derivatives of folic acid
CA2382499A1 (en) Method for coupling molecules
de Koning et al. Synthesis of thiol-modified peptide nucleic acids designed for post-assembly conjugation reactions
Nandhini et al. 2-Methoxy-4-methylsulfinylbenzyl Alcohol as a Safety-Catch Linker for the Fmoc/t Bu Solid-Phase Peptide Synthesis Strategy
KR100241948B1 (ko) N알파-2-(4-나이트로페닐설포닐)에톡시카르보닐-아미노산류
Aviñó et al. Synthesis of Oligonucleotide–Peptide Conjugates for Biomedical and Technological Applications
FI88031C (fi) 4-(substituerad aminokarbonyloximetyl)fenoxiaettiksyraderivat, foerfarande foer framstaellning av dessa och deras anvaendning i en fastfassyntes av peptid-aminoalkylamider
Oakley et al. Synthesis of a hybrid protein containing the iron-binding ligand of bleomycin and the DNA-binding domain of Hin
CA2408885A1 (en) Vectors for dna delivery
US6872809B2 (en) Nucleoside derivatives
KR20230147711A (ko) (폴리)펩타이드 및 올리고뉴클레오티드의 라이게이션 방법
KR20240077919A (ko) 링커-약물 접합체 제조방법
Alves et al. Synthesis and use of a pseudo‐cysteine for native chemical ligation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead